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Abstract
Chronic migraine (CM) is a clinically and epidemiologically important dis-
ease that generates considerable impairment to those affected by it, since there is 
evidence of higher incidence of depression, anxiety, and chronic pain in patients 
with this condition. It is characterized by the occurrence of headache for at least 8 
migraine days in a month and at least 15 headache days in the same month. Despite 
the similarity in CM presented in adults, when in adolescents it has some particu-
larities. Thus, the aim of this chapter was to conduct a literature review, using the 
databases: PubMed, SciELO, and LILACS, in addition to text books, explaining the 
definition, epidemiology, risk factors, diagnosis, pathophysiology, treatment, and 
prevention of CM in adolescent population.
Keywords: classic migraine, migraine with auras, epidemiology, adolescence, 
diagnosis
1. Introduction
Chronic migraine (CM) is defined as the occurrence of headache for at least 
8 migraine days in a month and at least 15 headache days in the same month [1], 
being much less common and more debilitating than episodic migraine. Evidence 
indicates that migraine is a progressive disorder [2–4], and therefore, diagnosis 
and early management of episodic migraine are recommended, in order to avoid 
its chronicity, especially in adolescents; however, there is a failure in the accuracy 
of the diagnosis of CM in this population [5]. Migraine in this population can be 
misdiagnosed as sinusitis, attempted school skipping, and cerebral neoplasia, which 
may culminate in unnecessary testing [6].
2. Epidemiology
CM is a common disorder in children, and its incidence in adolescents presents a 
considerable increase [7]. Irrespective of age, the prevalence of chronic migraine is 
estimated at 1.5–2% in general population. On the other hand, its prevalence is 3% 
(from 3 to 7 years of age), 4–11% (from 7 to 11 years of age), and 8–23% (at 11 years 
of age), with a mean age of onset of 7.2 years for male and 10.9 years for female [8, 
9]. Migraine is the 6th most disabling disease worldwide between the ages of 10 
and 14 years and the 5th between the ages of 15 and 19 years [10]. In addition to toe 
the line impact inflicted by pain itself, migraine generates serious consequences 
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in children’s and adolescent’s routine, since it is responsible for school absences, 
negatively affecting academic performance. It also has social impacts, since it 
hinders the child’s interactions with his peers, and economic, due to the costs 
generated by the treatment [11]. Migraine has two-fold higher prevalence in females 
when compared to their peer male adolescents [12–17]. In women, the prevalence 
of migraine increases during adolescence, presenting a maximum prevalence at 
30 years of age, decreasing sharply after menopause [12, 14, 17], since 50–60% of 
women report having migraine during their menstrual period [18]. In the American 
Migraine Prevalence and Prevention Study (AMPP), patients with CM presented 
with depression, anxiety, and chronic pain twice as much as patients with episodic 
migraine [17]. Abu-Arafeh et al., in 2010, estimated that the overall prevalence of 
migraine in children is 7.7% (9.7% in female and 6.0% in male), being more com-
mon in female after completing 11 years of age, in male before the age of 7, and 
being equal in both sexes between 7 and 11 years of age [19, 20]. In another study, 
WöberBingöl et al. reported general prevalence of migraine of 9.1% [21].
3. Risk factors
Among the risk factors for CM, the following are included:
a. gender (female, once migraine has been associated with menorrhagia, dysmen-
orrhoea, and endometriosis [22]);
b. age group;
c. ethnicity: more specifically, white;
d. genetic factors: family history of headache, mental disorders [5, 22, 23], anxiety, 
and depression [5, 23], as well as comorbidities, such as sleep disorders [5, 23] 
(sleep apnea syndrome and hypopnea, snoring, and insomnia [22]), obesity 
[23], epilepsy [24], hypertension, asthma, hypothyroidism, genitourinary disor-
ders, musculoskeletal disorders, [22] and gastrointestinal disorders [22, 24];
e. family and environmental factors: divorce [23], socioeconomic class [5, 23], 
and low level of education [5]; and
f. other factors: pro-thrombotic factors [5] and pro-inflammatory factors [5, 23].
In addition to the factors mentioned above, others still under study may be 
related to the pathophysiology of CM and, therefore, represent risk factors such as 
traumatic brain injury, epilepsy, hemodialysis, and excessive use of symptomatic 
medications.
The existence of correlation between CM and traumatic brain injury was the 
subject of a systematic review study published by Sowell et al., in 2017, in which 
was sought to relate it to posttraumatic chronic headache (PTCH) in children 
and adolescents. In this study, it was observed that 7.6% of children with PTCH 
presented migraine [24], thus disclosing it to be a relatively common condition and 
that it should be considered.
Another factor that may be correlated with CM is epilepsy. Both migraine 
and epilepsy are considered neuronal hyperarousal-related diseases which can 
be partially prevented by antiepileptic drugs. According to the Center of Disease 
Control (CDC), 16.2% of adults with no history of epilepsy have severe headache or 
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migraine, while those with active epilepsy have 35.5% of prevalence [25]. Therefore, 
although the correlation between epilepsy and migraine has not been completely 
elucidated yet, there are strong indications for such an interdependence.
Regarding hemodialysis in pediatric and adolescent patients with chronic kidney 
disease, Davidovits and Eidlitz Markus, in a study published in the International 
Headache Society, concluded a three-fold higher prevalence of headache among 
patients in hemodialysis compared to those with chronic kidney disease without 
this treatment, the most commonly described type of headache being migraine. 
Furthermore, other variables were associated with headaches, such as anemia, 
hyperparathyroidism, and low glomerular filtration [26].
Notwithstanding, excessive symptomatic medication is also described in the 
literature as a risk factor for CM. With this in mind, Rojo et al. made a comparison 
between patients with CM with and without excessive medication use (analgesics, 
tryptans, ergotamine, and opioids). In the study, it was observed that individuals 
overusing symptomatic medication had the onset of migraine at a younger age, with 
a longer progression time before looking for a specialist, as well as a higher percent-
age of preventive prior treatment (mainly antidepressants), compared to those 
without excessive use of medication [5].
4. Diagnosis
Even though there are differences between the clinical findings of CM in the 
pediatric population and other age groups, due to the scarce evidence in rela-
tion to diagnostic methods aimed specifically at these patients, the International 
Classification of Headache Disorders, of Headache Classification Committee of the 
International Headache Society (IHS), 2018, is used, the same applied to the adult 
population [1, 5].
According to IHS, CM is characterized by occurrence of ≥8 days of migraine 
in a month and ≥15 headache days. Migraine attacks can be with and/or without 
aura [1]. In this case, migraine without aura is a headache lasting 4–72 h, which has 
at least two of the following characteristics: (1) unilateral location; (2) pulsatile 
character; (3) moderate to strong pain intensity; and (4) is exacerbated by routine 
physical activities and, during the headache, the patient has at least one of the 
following symptoms: (1) nausea and/or vomiting; (2) photophobia; and (3) phono-
phobia [1].
On the other hand, migraine with aura is a headache with the same character-
istics mentioned above, plus one or more symptoms of fully reversible aura, and 
may be visual, sensory, speech and/or language, motor, brain stem, or retinal. 
Furthermore, crises should have at least three of the following characteristics: (1) 
at least one symptom of aura gradually spreads for more than 5 min; (2) two or 
more aura symptoms occur in succession; (3) each individual aura symptom lasts 
5–60 min; (4) at least one symptom of aura is unilateral; (5) at least one symptom 
of aura is positive; and (6) aura is accompanied, or followed within 60 min, by 
headache [1].
Although the use of IHS criteria is recommended, the health professional should 
know the peculiarities of CM in adolescent population in order to complement the 
diagnosis. The characteristics of the headache tend to be more prominent in this 
group, since the brain is in the growth and development process. Furthermore, 
the duration of pain crises may be less than 1 h, contrary to the IHS criteria, which 
mentions a minimum duration of 2 h [1, 6, 27]. A direct relation between the 
patient’s age and duration of crises is observed, being younger shorter the dura-
tion of the crisis [4]. An important information is that adolescents may present 
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nonpulsatile and bilateral pain, which may induce the misdiagnosis of tensional 
headache [2, 6, 27].
Approximately 10% of young people with migraine present aura, from visual, 
sensory, speech, or language disorders, motor, or brain stem changes, manifesting 
themselves as scotomas, paresthesias, dysphasias, hemiplegia, ataxia, or confu-
sion. The suspicion of other diseases of the central nervous system should be listed 
through fever, nuchal stiffness, altered mental status, absence of family history of 
migraine, occipital or positional headaches, or headaches that constantly awaken 
the individual during sleep [28–30].
In adolescents, it is common for patients with migraine to have comorbidities 
such as epilepsy and atopy. The most common atopic disorders reported concomi-
tantly with CM are seasonal rhinitis, conjunctivitis, and asthma, with correlation 
with positive family history. Regarding epilepsy, it is mainly associated with 
migraine with aura, which corroborates the role of depression of cortical propaga-
tion. Another hypothesis is that both, migraine and epilepsy, have the influence of 
canalopathies on their pathophysiology [30–32].
5. Pathophysiology
The mechanisms responsible for the occurrence of CM are not yet fully under-
stood. Thus, the existing model to explain its pathophysiology still has gaps. It is 
accepted that migraine occurs by complex mechanisms involving activation and 
sensitization of trigeminal nociceptive pathways, especially its ophythalmic divi-
sion, changes of the autonomic nervous system function, descending pain modula-
tor system dysfunction, thalamic sensitization, and central sensitization due to the 
excessive use of medication in the acute treatment of pain crises.
It is noteworthy that the córtex of patients with migraine is hyperexcitable and 
abnormally sensitive to external stimuli. Due to triggering factors, the so-called 
cortical spreading depression (CSD) occurs, characterized by a slow propagation 
wave (2–6 mm/min) of sustained neuronal depolarization, which generates a 
transient peak of intense activity as it progresses in the tissue, followed by a long-
term neural suppression. That is, there is a period of electrochemical hyperactivity 
followed by cortical inactivity, which results in the release of substances in the 
extracelular environment (ECE), such as K+ and H+ ions, nitric oxide, arachi-
donic acid, and prostaglandins [33–35]. Such a change in the ECE may activate or 
sensitize trigeminal afferences. The trigeminal ganglia, once stimulated, releases 
neuropeptides, causing inflammation of the dura mater. Cernuda-Morollón 
et al. demonstrate in their studies that interictal levels of calcitonin gene-related 
peptide (CGRP) and intestinal vasoactive peptide (IVP) are higher in CM [36, 37]. 
Thus, meningeal inflammation occurs, with vasodilation and endotelial dysfunc-
tion, resulting in plasma leakage and release of more inflammatory cytokines by 
mast cells. Thereby, neurogenic inflammation can lead to activation and sensitiza-
tion of meningeal trigeminal afferences—a phenomenon known as peripheral 
sensitization [38–40].
A widely spread hypothesis is that increased peripheral nociceptive processing 
triggers increased activity of the descending pain modulation system, resulting in 
increased oxidative stress and consequent nociceptive modulation, further lowering 
the threshold for new pain crises. However, so far studies have not shown associa-
tion between gene polymorphisms associated with oxidative stress and the occur-
rence of CM. On the other hand, repetitive painful stimuli on the trigeminal nerve 
cause activation of the pain modulating descending system in several portions, 
including the periaqueductal gray matter, showing that during migraine attacks, the 
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neurons of this region show increased activity, which may lead to oxidative stress 
and finally dysfunction of nociceptive modulation by such system [33, 41–43].
Thalamic modulation of trigeminal afferences appears to be related to the devel-
opment of cutaneous allodynia in migraine, as sensitized thalamic neurons process 
nociceptive information from cranial meninges, along with sensory information 
from the scalp, skin, face, body, and limbs. Furthermore, the use of drugs that act 
modulating trigeminal afferences on the thalamus is effective in the preventive 
treatment of migraine attacks, such as topiramate, sodium valproate, and CGR66 
receptor antagonists, corroborating the role of this structure in the chronicity of 
migraine [44–47].
The overuse of medications to relieve acute migraine may also lead to the 
chronicity of this condition, through the drug-mediated central sensitization 
mechanism, leading to increased susceptibility to cortical spreading depression. 
Central sensitization manifests clinically from increased pericranial sensitivity and 
allodynia [48–50].
Andersen et al. demonstrated in 2016 that during pain crises serum miRNA 
changes occur, and in patients with CM such changes persist the same in periods 
without pain. This implies the possibility of serum miRNA changes as a pathogenic 
feature of migraine. Thus, the study suggests that serum miRNA dosage is a poten-
tial biomarker of this disease [51].
According to Oakley et al., there is a possibility that obesity may be involved in 
the pathophysiology of migraine in the pediatric population. It is hypothesized that 
there is an overlap of the central and peripheral neural pathways responsible for the 
regulation of diet and those linked to the pathogenesis of migraine [33, 52]. Peterlin 
et al. demonstrated that several hypothalamic peptides, proteins, and neurotrans-
mitters involved in the mechanisms of hunger also participate in the pathophysiol-
ogy of migraine, such as serotonin, orexin, and adipokines. It is possible that the 
release of these substances, associated with the mechanism of diet and/or obesity 
states, may act as a trigger or corroborate the development of migraine. There is also 
the possibility that lifestyle and behavioral differences influence the relationship 
between migraine and obesity, such as differences in diet and physical exercise, or 
the lack of it [33, 53].
6. Treatment
6.1 General and supportive measures
The treatment of chronic migraine in adolescents aims not only to reduce 
frequency, duration, and intensity of the headache attacks, but also to reduce the con-
sequences of this condition on the patient’s quality of life, seeing as he or she is going 
through a process of growth and development. It also aims to treat comorbidities and 
reduce the social impact of the disease, such as school absences, school underachieve-
ment, and reduced peer interactions. Thus, the treatment should be developed from 
a multiprofessional perspective, with the help of pediatricians, neurologists and 
psychiatrists, psychologists, educators, and nutritionists, among others [54].
Firstly, family members should receive detailed information about the adoles-
cent’s diagnosis and ensure that the condition is not secondary to malignant diseases, 
in order to transmit confidence to the patient and their parents, thus contributing to 
treatment adherence [5].
Proper living habits are of paramount importance for treatment. However, the 
health professional should be careful to not excessively restrict the activities of 
young people, as this may lead to difficulties in adherence [55].
Migraine
6
Sleep disorders are important comorbidities of chronic migraine. Therefore, 
regular sleep habits should be advocated in order to promote restful and restorative 
sleep. For this, the teenager can use some techniques, such as scheduling a daily 
bedtime, avoid using electronic media when in bed, avoid eating 4 h before bed-
time, and avoid daytime naps. Still, sleep deprivation can be a triggering factor for 
pain crises, corroborating the importance of a well-slept night [56, 57].
Regarding food, it is important to prioritize regular meals, with the consump-
tion of healthy foods and adequate hydration. Caffeine and tobacco should be 
avoided. The performance of physical activities should be encouraged, as it not only 
reduces the occurrence of crises, but also is able to assist in the treatment of depres-
sion and anxiety comorbidities, when present [58, 59].
Gelfand et al. emphasize that the patient should be alerted about the negative 
effects of overuse of medications, as it is one of the factors responsible for the 
chronicity of migraine, from the central sensitization mechanism, as previously 
explained about the pathophysiology [60].
Kroon Van Diest et al. [61], based on a randomized study, demonstrated the 
importance of Cognitive Behavioral Therapy (CBT) for adherence to pharmacologi-
cal treatment and institution of lifestyle changes [62]. CBT aims, through interven-
tions guided by a psychologist, to promote the patient’s active learning in order to 
implement skills to deal with migraine and related conditions and situations to her. 
Thus, during the sessions, behavioral coping skills are worked out, such as problem-
solving and thought restructuring, that is, the adolescent is urged to change their 
ideas, beliefs, and attitudes regarding his chronic condition [62]. CBT, in combina-
tion with amitriptyline, is suggested as a first-line treatment in the context of CM in 
adolescents [61].
6.2 Acute treatment
Regarding acute pharmacological treatment, that is, to relieve pain crises, nonste-
roidal anti-inflammatory drugs (NSAIDs) and triptans are used [28, 63, 64]. Among 
NSAIDs, the most used are ibuprofen and naproxen [28]. Evers et al. demonstrated 
that ibuprofen is better than placebo. There is no evidence regarding the efficacy of 
acetaminophen in adolescents [63, 65, 66].
In the adolescent population, the following triptans are indicated: sumatrip-
tan, rizatriptan, zolmitriptan, and almotriptan. Studies indicate that such drugs 
are the most effective in relieving pain during acute crises in adolescents, with 
no statistically significant differences between them [63]. According to Derosier 
et al., the combination of naproxen and sumatriptan was superior to placebo when 
analyzing the permanence of analgesia after 2 h, with sumatriptan + naproxen 
sodium 10 mg + 60 mg (29%; p = 0,003), 30 mg + 180 mg (27%; p = 0.003), and 
85 mg + 500 mg (24%; p = 0.003) versus placebo (10%) [67]. Among the side 
effects of this class, the most common are mild fatigue, paresthesia, dizziness, and 
taste disorders [28, 64].
In the case of long-term migraine or migratory status, that is, disabling cri-
sis lasting more than 72 h, hospital treatment may be required for intravenous 
administration of prochlorperazine with ketorolac, which Brousseau showed that 
57% of patients had pain reduction in 60 min [28, 68]. Dihydroergotamine (DHE) 
has been shown to be well tolerated and effective in acute treatment and is gener-
ally administered in hospital setting, and an association with metoclopramide or 
prochlorperazine is suggested, which is able to attenuate gastrointestinal side effects 
[28, 69]. Ayulo et al. suggested the use of intravenous lidocaine for the treatment of 
migratory status in adolescents, but further evidence is needed to ensure the long-
term efficacy and safety of this medication [28, 70].
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6.3 Preventive treatment
Prevention of chronic migraine attacks in adolescents remains limited [71, 72]. 
Newly developed therapies, including drugs, biologic products, and neuromodula-
tion devices are safe and well tolerated in adults [73–80]. Studies in the pediatric 
population are still being developed [81]. Therefore, the current nonpediatric 
prevention will be presented.
Epidemiological studies suggest that approximately 38% of migraine patients 
require preventive therapy, however, only 3–13% currently use it [12]. The prevention 
of CM currently presents concrete evidence for the following drugs: onabotulinumtox-
ina [82], topiramate [83, 84], and fremanezumab (TEV-48125) [85]. Other therapies, 
such as β-blockers and amitriptyline, are often used despite the lack of evidence, as 
they are not fully effective or poorly tolerated, which may culminate in low adherence 
rates [85]. However, a randomized study developed by Powers et at. demonstrated that 
amitriptyline, when combined with Cognitive Behavioral Therapy (CBT), reduces 
migraine disability and pain days by 1 month—adolescents receiving amitriptyline 
alone (group A) reduced the number of days with headache in 1 month of 6.8 days, 
while those who associated amitriptyline with CBT (group B) had a reduction of 
11.5 days; headache disability as assessed by the Pediatric Migraine Disability Score 
(PedMIDAS) decreased by 52.7 points in group B versus 38.6 points in group A [62].
Currently, new forms of prevention have been proposed, based on the under-
standing of the pathophysiology of the disease. The calcitonin gene-related peptide 
(CGRP) has increased plasma concentration during a migraine attack [86–88]. 
Therefore, a human monoclonal antibody against the receptor of CGRP, named 
Galcanezumab, which was effective in preventing migraine when given at a dose 
of 150 mg twice a month, was developed in a study by Skljarevski et al. [89]. 
Treatment with self-administered injections of subcutaneous galcanezumab [90], 
subcutaneous fremanezumab [91], and enerumab [92] was associated with a reduc-
tion in the number of monthly days of migraine (5.6–6.5 days, 1.3–1.5 days, and 
6.6 days, respectively).
Recent studies indicate that nonpharmacological strategies are effective in pre-
venting CM, reducing the activation of peripheral nociceptive terminations. This 
can be accomplished by manipulation technique, increasing the range of motion 
and reducing the stiffness of the cervicothoracic spine. In the study by Gandolfi 
et al., patients undergoing this treatment had lower consumption of analgesics, 
NSAIDs, and triptans [93].
Guilbot et al. showed that Tanacetum parthenium L., magnesium, and coenzyme 
Q10, administered prophylactically for 3 months significantly reduced the number 
of monthly migraine days (4.9 ± 2.6 days) [94]. Silberstein et al. proposed the pre-
vention of CM with noninvasive vagal stimulation, which presented better results 
in patients who underwent longer treatment times (6 months, in the study) [95].
7. Conclusion
CM in adolescents is a disease of clinical and epidemiological importance, since 
it can affect approximately a quarter of the pediatric population with an average 
of 11 years of age, being considered debilitating due to psychological, social, and 
economic repercussions.
This disorder has intrinsic and nonmodifiable (genetic and comorbidities) risk 
factors, as well as modifiable risk factors, such as behavioral and socioenviron-
mental variables, in addition to several other elements still under study that may 
contribute to the onset or that are correlated.
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The diagnosis of migraine is made clinically according to the ICHD-3 criteria, 
taking into account the particularities of the adolescent population.
Pathophysiology, as well as risk factors and prevention, are still not completely 
elucidated items in CM. However, it is generally agreed that migraine occurs from 
complex mechanisms involving activation and sensitization of trigeminal nocicep-
tives pathways, alteration of autonomic nervous system function, pain modulating 
descending system dysfunction, thalamic sensitization and further central sensiti-
zation due to the overuse of medicines in the acute treatment of pain crises.
Treatment, in turn, is multiprofessional and supported by both pharmacologi-
cal and nonpharmacological measures. Nonpharmacological measures include 
guidance to parents and family members about the chronic condition, as well as 
sleep hygiene and adoption of good eating habits by the patient. In the case of drug 
measures, NSAIDs and triptans are the first option and, in case of migraine status, 
prochlorperazine associated with intravenous ketorolac added to recent evidence 
suggesting the use of intravenous lidocaine.
Finally, studies are still needed to fill the gaps present for the complete under-
standing of this complex and debilitating entity that is chronic migraine. Through 
a better understanding of the pathophysiological mechanisms responsible for the 
development of CM, as well as its risk factors, it will be possible to develop more 
effective prevention and treatment methods in adolescents.
Author details
Marcos Antonio da Silva Cristovam1*, Daniel Albiero Piélak2, Júlia Deitos3,  
Júlia Natsumi Hashimoto3, Lorena Vaz Meleiro Lopes3 and Luísa Manfredin Vila3
1 Clinical Pediatrics of Western Paraná State University, Cascavel, PR, Brazil
2 Western Paraná Universitary Hospital of Western Paraná State University, 
Cascavel, PR, Brazil
3 Western Paraná State University School of Medicine, Cascavel, PR, Brazil
*Address all correspondence to: ma.cristovam@uol.com.br
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
9Chronic Migraine in Adolescence
DOI: http://dx.doi.org/10.5772/intechopen.90936
References
[1] Headache Classification Committee 
of the International Headache Society 
(IHS). The international classification 
of headache disorders. Cephalalgia. 
2018;38(1):1-211
[2] Lipton RB, Silberstein SD. Episodic 
and chronic migraine headache: 
Breaking down barriers to optimal 
treatment and prevention. Headache. 
2015;55(2):103-122
[3] Lipton RB, Pan J. Is migraine a 
progressive brain disease? Journal of 
the American Medical Association. 
2004;291(4):493-494
[4] Lipton RB, Bigal ME. Migraine: 
Epidemiology, impact, and risk 
factors for progression. Headache. 
2005;45(1):3-13
[5] Özge A, Yalın OÖ. Chronic 
migraine in children and adolescents. 
Current Pain and Headache Reports. 
2016;20(2):1-7. DOI: 10.1007/
s11916-016-0538-z
[6] Gelfand AA. Migraine in young 
children. Developmental Medicine and 
Child Neurology. 2015;57(6):503
[7] Victor TW, Hu X, Campbell JC, 
Buse DC, Lipton RB. Migraine prevalence 
by age and sex in the United States: 
A life-span study. Cephalalgia. 
2010;30:1065-1072
[8] Stewart WF, Linet MS, Celentano DD, 
Van Natta M, Siegler D. Age and sex-
specific incidence rates of migraine with 
and without visual aura. American Journal 
of Epidemiology. 1991;34:1111-1120
[9] Stewart WF, Lipton RB, Celentano  
DD, Reed ML. Prevalence of migraine 
headache in the United States. Journal 
of the American Medical Association. 
1992;267:64-69
[10] GBD 2015 Disease and Injury  
Incidence and Prevalence 
Collaborators. Global, regional, and 
national incidence, prevalence, and 
years lived with disability for 310 
diseases and injuries, 1990-2015: A 
systematic analysis for the Global 
Burden of Disease Study 2015. Lancet. 
2016;388:1545-1602
[11] Arruda MA, Bigal ME. Migraine 
and migraine subtypes in 
preadolescent children: Association 
with school performance. Neurology. 
2012;79:1881-1888
[12] Lipton RB, Bigal ME, 
Diamond M, Freitag F, Reed ML, 
Stewart WF. Migraine prevalence, 
disease burden, and the need for 
preventive therapy. Neurology. 
2007;68:343-349
[13] Bigal ME, Liberman JN, Lipton RB. 
Age-dependent prevalence and clinical 
features of migraine. Neurology. 
2006;67:246-251
[14] Steiner TJ, Scher AI, Stewart WF,  
Kolodner K, Liberman J, Lipton RB. The 
prevalence and disability burden of 
adult migraine in England and their 
relationships to age, gender and 
ethnicity. Cephalalgia. 2003; 
23:519-527
[15] Ando N, Fujimoto S, Ishikawa T,  
et al. Prevalence and features of 
migraine in Japanese junior high 
school students aged 12-15 yr. Brain & 
Development. 2007;29:482-485
[16] Zencir M, Ergin H, Sahiner T, et al. 
Epidemiology and symptomatology 
of migraine among school children: 
Denizli urban area in Turkey. Headache. 
2004;44:780-785
[17] Lipton RB, Stewart WF, Diamond S, 
Diamond ML, Reed M. Prevalence and 
burden of migraine in the United States: 
Data from the American migraine study 
II. Headache. 2001;41:646-657
Migraine
10
[18] Granella F, Sances G, Zanferrari C,  
Costa A, Martignoni E, Manzoni GC. 
Migraine without aura and reproductive 
life events: A clinical epidemiological 
study in 1300 women. Headache. 
1993;33:385-389
[19] Abu-Arafeh I, Razak S,  
Sivaraman B, et al. Prevalence of 
headache and migraine in children 
and adolescents: A systematic 
review of population-based studies. 
Developmental Medicine and Child 
Neurology. 2010;52(12):1088-1097
[20] Mehta S. Study of various social 
and demographic variables associated 
with primary headache disorders in 500 
school-going children of central India. 
Journal of Pediatric Neurosciences. 
2015;10(1):13
[21] Wöber-Bingöl Ç. Epidemiology of 
migraine and headache in children and 
adolescents. Current Pain and Headache 
Reports. 2013;17(6):1-11
[22] Spierings ELH, Padamsee A. 
Menstrual-cycle and menstruation 
disorders in episodic vs chronic 
migraine: An exploratory study. Pain 
Medicine. 2015;16(7):1426-1432. DOI: 
10.1111/pme.12788
[23] Rojo E, Pedraza MI, Muñoz I, 
Mulero P, Ruiz M, de la Cruz C, et al. 
Diferencias entre migraña crónica 
con y sin uso excesivo de medicación: 
Experiencia en una serie hospitalaria 
de 434 pacientes. Neurología. 
2015;30(3):153-157. DOI: 10.1016/j.
nrl.2013.12.003
[24] Sowell MK, Youssef PE. The 
comorbidity of migraine and epilepsy 
in children and adolescents. Seminars in 
Pediatric Neurology. 2016;23(1):8391. 
DOI: 10.1016/j.spen.2016.01.012
[25] Shaw L, Morozova M, Abu-Arafeh I. 
Chronic post-traumatic headache in 
children and adolescents: Systematic 
review of prevalence and headache 
features. Pain Management. 
2018;8(1):57-64. DOI: 10.2217/
pmt-2017-0019
[26] Davidovits M, Eidlitz Markus T. 
Headache in pediatric and adolescent 
patients with chronic kidney disease, 
with and without hemodialysis: 
A comparative cohort study. 
Cephalalgia. 2017;38(5):883-891. DOI: 
10.1177/0333102417719235
[27] Mariani R, Torriero R, Capuano A, 
et al. Clinical characteristics of primary 
headaches in children younger than 6 
years. Cephalalgia. 2015;35:7-7
[28] Slater SK, Powers SW, 
O’Brien HL. Migraine in children. 
Current Opinion in Pediatrics. 
2018;1:775-778. DOI:10.1097/
mop.0000000000000694
[29] Lewis DW, Ashwal S, Dahl G, 
et al. Practice parameter: Evaluation of 
children and adolescents with recurrent 
headaches: Report of the quality 
standards Subcommittee of the American 
Academy of neurology and the practice 
Committee of the Child Neurology 
Society. Neurology. 2002;59:490-498
[30] Newton RW. Childhood headache. 
Archives of Disease in Childhood. 
Education and Practice Edition. 
2008;93:105
[31] Özge A, Öksüz N, Ayta S, et al. 
Atopic disorders are more common 
in childhood migraine and correlated 
headache phenotype. Pediatrics 
International. 2014;56(6):868-872
[32] Bellini B, Arruda M, Cescut A, 
et al. Headache and comorbidity in 
children and adolescents. The Journal of 
Headache and Pain. 2013;14(1):79
[33] May A, Schulte LH. Chronic 
migraine: Risk factors, mechanisms and 
treatment. Nature Reviews Neurology. 
2016;12(8):455-464. DOI: 10.1038/
nrneurol.2016.93
11
Chronic Migraine in Adolescence
DOI: http://dx.doi.org/10.5772/intechopen.90936
[34] Durham P, Papapetropoulos S. 
Biomarkers associated with migraine 
and their potential role in migraine 
management. Headache: The Journal of 
Head and Face Pain. 2013;53(8): 
1262-1277. DOI: 10.1111/head.12174
[35] Vecchia D, Pietrobon D. Migraine: A 
disorder of brain excitatory-inhibitory 
balance? Trends in Neurosciences. 
2012;35:507-520
[36] Cernuda-Morollón E et al. 
Increased VIP levels in peripheral blood 
outside migraine attacks as a potential 
biomarker of cranial parasympathetic 
activation in chronic migraine. 
Cephalalgia. 2015;35:310-316
[37] Cernuda-Morollón E et al. 
Interictal increase of CGRP levels 
in peripheral blood as a biomarker 
for chronic migraine. Neurology. 
2013;81:1191-1196
[38] Waeber C, Moskowitz MA. Migraine 
as an inflammatory disorder. Neurology. 
2005;64:S9-S15
[39] Levy D. Migraine pain, meningeal 
inflammation, and mast cells. 
Current Pain and Headache Reports. 
2009;13:237-240
[40] Pietrobon D, Moskowitz MA. 
Pathophysiology of migraine. Annual 
Review of Physiology. 2013;75(1): 
365-391. DOI: 10.1146/annurev- 
physiol-030212-183717
[41] Schulte LH, Sprenger C, May A. 
Physiological brainstem mechanisms of 
trigeminal nociception: An fMRI study 
at 3T. NeuroImage. 2015;124:518-525
[42] Youssef AM, Macefield VG, 
Henderson LA. Pain inhibits pain; 
human brainstem mechanisms. 
NeuroImage. 2016;124(Pt A):54-62
[43] Gentile G et al. Lack of association 
between oxidative stress-related gene 
polymorphisms and chronic migraine in 
an Italian population. Expert Review of 
Neurotherapeutics. 2015;15:215-225
[44] Burstein R et al. Thalamic 
sensitization transforms localized pain 
into widespread allodynia. Annals of 
Neurology. 2010;68:81-91
[45] Andreou AP, Goadsby PJ.  
Topiramate in the treatment of 
migraine: A kainate (glutamate) 
receptor antagonist within the 
trigeminothalamic pathway. 
Cephalalgia. 2011;31:1343-1358
[46] Andreou AP, Shields KG, 
Goadsby PJ. GABA and valproate 
modulate trigeminovascular 
nociceptive transmission in the 
thalamus. Neurobiology of Disease. 
2010;37:314-323
[47] Summ O, Charbit AR, 
Andreou AP, Goadsby PJ. Modulation 
of nocioceptive transmission with 
calcitonin gene-related peptide 
receptor antagonists in the thalamus. 
Brain. 2010;133(9):2540-2548. DOI: 
10.1093/brain/awq224
[48] De Felice M et al. Triptan-induced 
latent sensitization: A possible basis for 
medication overuse headache. Annals of 
Neurology. 2010;67:325-337
[49] Green AL et al. Increased 
susceptibility to cortical spreading 
depression in an animal model 
of medication-overuse headache. 
Cephalalgia. 2014;34:594-604
[50] Becerra L et al. Triptans disrupt 
brain networks and promote stress-
induced CSD-like responses in cortical 
and subcortical areas. Journal of 
Neurophysiology. 2016;115:208-217
[51] Andersen HH, Duroux M, 
Gazerani P. Serum MicroRNA signatures 
in Migraineurs during attacks and 
in pain-free periods. Molecular 
Neurobiology. 2015;53(3):1494-1500. 
DOI: 10.1007/s12035-015-9106-5
Migraine
12
[52] Oakley CB, Scher AI, Recober A, 
Peterlin BL. Headache and obesity in 
the pediatric population. Current Pain 
and Headache Reports. 2014;18(5):1-12. 
DOI: 10.1007/s11916-014-0416-5
[53] Peterlin BL, Tietjen GE, Gower BA, 
et al. Ictal adiponectin levels in episodic 
migraineurs: A randomized pilot trial. 
Headache. 2013;53:474-490
[54] De Angelis V, Cherubini F, 
Nigrelli G, Erbuto D, Marteletti P. 
Multimodal therapy in the management 
of MOH: 3 year experience. The Journal 
of Headache and Pain. 2015;16:135
[55] Sieberg CB, Huguet A, von 
Baeyer CL, Seshia S. Psychological 
interventions for headache in children 
and adolescents. The Canadian 
Journal of Neurological Sciences. 
2012;39(01):26-34
[56] Guidetti V, Dosi C, Bruni O. The 
relationship between sleep and headache 
in children: Implications for treatment. 
Cephalalgia. 2014;34(10):767-776
[57] Calhoun AH, Ford S. Behavioral 
sleep modification may revert 
transformed migraine to 
episodic migraine. Headache. 
2007;478(11):787-811
[58] Straube A, Heinen F, Ebinger F, von 
Kries R. Headache in school children: 
Prevalence and risk factors. 
Deutsches Ärzteblatt International. 
2013;6(57):811-818
[59] Verotti A, Di Fonzo A, Penta L, 
Agostinelli S, Parisi P. Obesity and 
headache/migraine: The importance 
of weight reduction through lifestyle 
modifications. BioMed Research 
International. 2014;2014:420858
[60] Gelfand AA, Goadsby PJ. 
Medication overuse in children and 
adolescents. Current Pain and Headache 
Reports. 2014;18(7):1-6
[61] Kroon Van Diest AM, Ramsey RR, 
Kashikar-Zuck S, Slater S, Hommel K, 
Kroner JW, et al. Treatment adherence 
in child and adolescent chronic migraine 
patients. The Clinical Journal of Pain. 
2017;33(10):892-898. DOI: 10.1097/
ajp.0000000000000481
[62] Powers SW, Kashikar-Zuck SM, 
Allen JR, et al. Cognitive behavioral 
therapy plus amitriptyline for chronic 
migraine in children and adolescents: 
A randomized clinical trial. Journal 
of the American Medical Association. 
2013;310(24):2622-2630
[63] Richer L, Billinghurst L, 
Linsdell MA, Russell K, Vandermeer B, 
Crumley ET, et al. Drugs for the acute 
treatment of migraine in children and 
adolescents. Paediatrics & Child Health. 
2017;22(8):454-458. DOI: 10.1093/pch/
pxx170
[64] Patniyot IR, Gelfand AA. Acute 
treatment therapies for pediatric 
migraine: A qualitative systematic 
review. Headache. 2016;56:49-70
[65] Evers S, Rahmann A, Kraemer C, 
Kurlemann G, Debus O, Husstedt IW, 
et al. Treatment of childhood migraine 
attacks with oral zolmitriptan 
and ibuprofen. Neurology. 
2006;67(3):497-499. DOI: 10.1212/01.
wnl.0000231138.18629.d5
[66] Lewis DW, Kellstein D, Dahl G, 
Burke B, Frank LM, Toor S, et al. 
Children’s ibuprofen suspension for the 
acute treatment of pediatric migraine. 
Headache. 2002;42(8):780-786. DOI: 
10.1046/j.1526-4610.2002.02180.x
[67] Derosier FJ, Lewis D, Hershey AD, 
Winner PK, Pearlman E, Rothner AD, 
et al. Randomized trial of sumatriptan 
and naproxen sodium combination 
in adolescent migraine. Pediatrics. 
2012;129(6):e1411-e1420. DOI: 10.1542/
peds.2011-2455
13
Chronic Migraine in Adolescence
DOI: http://dx.doi.org/10.5772/intechopen.90936
[68] Brousseau DC, Duffy SJ, 
Anderson AC, Linakis JG. Treatment 
of pediatric migraine headaches: A 
randomized, double-blind trial of 
prochlorperizine versus ketorolac. 
Annals of Emergency Medicine. 
2004;42:256-262
[69] Kabbouche MA, Powers SW, 
Hershey AD, et al. Inpatient treatment 
of status migraine with 
dihydroergotamine in children and 
adolescents. Headache. 2009;49:106-109
[70] Ayulo MA Jr, Philips KE, 
Tripathi S. Safety and efficacy of IV 
Lidocaine in the treatment of children 
and adolescents with status migraine. 
Pediatric Critical Care Medicine. 
2018;19:755-759
[71] Lewis D, Ashwal S, Hershey A, et al. 
Practice parameter: Pharmacological 
treatment of migraine headache in 
children and adolescents: Report of 
the American Academy of Neurology 
quality standards subcommittee 
and the practice Committee of the 
Child Neurology Society. Neurology. 
2004;63:2215-2224
[72] Jackson JL. Pediatric migraine 
headache—Still searching for effective 
treatments. The New England Journal of 
Medicine. 2017;376:169-170
[73] Silberstein SD et al. Fremanezumab 
for the preventive treatment of chronic 
migraine. The New England Journal of 
Medicine. 2017;377:2113-2122
[74] Misra UK, Kalita J, Bhoi SK. High 
frequency repetitive transcranial 
magnetic stimulation (rTMS) is 
effective in migraine prophylaxis: 
An open labeled study. Neurological 
Research. 2012;34:547-551
[75] Goadsby PJ, Reuter U, Hallström Y, 
et al. A controlled trial of erenumab for 
episodic migraine. The New England 
Journal of Medicine. 2017;377:2123-2132
[76] Detke HC, Goadsby PJ, Wang S, 
Friedman DI, Selzler KJ, Aurora SK. 
Galcanezumab in chronic migraine: 10 
month 2019 the randomized, double-
blind, placebo-controlled REGAIN 
study. Neurology. 2018;91:e2211-e2221
[77] Chou DE, Shnayderman Yugrakh M, 
Winegarner D, Rowe V, Kuruvilla D, 
Schoenen J. Acute migraine therapy with 
external trigeminal neurostimulation 
(ACME): A randomized controlled trial. 
Cephalalgia. 2019;39:3-14
[78] Martelletti P, Barbanti P, Grazzi L, 
et al. Consistent effects of non-invasive 
vagus nerve stimulation (nVNS) for the 
acute treatment of migraine: Additional 
findings from the randomized, sham-
controlled, double-blind PRESTO trial. 
The Journal of Headache and Pain. 
2018;19:101
[79] Kuca B, Silberstein SD, Wietecha L, 
et al. Lasmiditan is an effective acute 
treatment for migraine: A phase 
3 randomized study. Neurology. 
2018;91:e2222-e2232
[80] Voss T, Lipton RB, Dodick DW, 
et al. A phase IIb randomized, double-
blind, placebo-controlled trial 
of ubrogepant for the acute 
treatment of migraine. Cephalalgia. 
2016;36:887-898
[81] Hornik CP, Gelfand AA,  
Szperka CL, Pezzuto T, Utevsky A,  
Kessel S, et al. Development of a 
prospective real-world data clinical 
registry of children and adolescents 
with migraine. Headache: The Journal 
of Head and Face Pain. 2019;0:2-9. DOI: 
10.1111/head.13714
[82] Dodick DW, Turkel CC, 
DeGryse RE, et al. OnabotulinumtoxinA 
for treatment of chronic migraine: 
Pooled results from the double-blind, 
randomized, placebo-controlled phases 
of the PREEMPT clinical program. 
Headache. 2010;50:921-936
Migraine
14
[83] Silberstein S, Lipton R, Dodick D, 
et al. Topiramate treatment of chronic 
migraine: A randomized, placebo-
controlled trial of quality of life and 
other efficacy measures. Headache. 
2009;49:1153-1162
[84] Silberstein SD, Lipton RB, 
Dodick DW, et al. Efficacy and safety of 
topiramate for the treatment of chronic 
migraine: A randomized, double-blind, 
placebo-controlled trial. Headache. 
2007;47:170-180
[85] Bigal ME, Edvinsson L, 
Rapoport AM, et al. Safety, tolerability, 
and efficacy of TEV-48125 for preventive 
treatment of chronic migraine: A 
multicentre, randomised, double-blind, 
placebo-controlled, phase 2b study. 
Lancet Neurology. 2015;14:1091-1100
[86] Goadsby PJ, Edvinsson L, 
Ekman R. Vasoactive peptide release in 
the extracerebral circulation of humans 
during migraine headache. Annals of 
Neurology. 1990;28(2):183-187
[87] Goadsby PJ, Edvinsson L. The 
trigeminovascular system and migraine: 
Studies characterizing cerebrovascular 
and neuropeptide changes seen in 
humans and cats. Annals of Neurology. 
1993;33(1):48-56
[88] Juhasz G, Zsombok T, Modos EA, 
et al. NO-induced migraine attack: 
Strong increase in plasma calcitonin 
gene-related peptide (CGRP) 
concentration and negative correlation 
with platelet serotonin release. Pain. 
2003;106(3):461-470
[89] Skljarevski V, Oakes TM, Zhang 
Q , Ferguson MB, Martinez J, 
Camporeale A, et al. Effect of different 
doses of galcanezumab vs placebo for 
episodic migraine prevention. JAMA 
Neurology. 2018;75(2):187. DOI: 
10.1001/jamaneurol.2017.3859
[90] Camporeale A, Kudrow D, Sides R 
Wang S, Van Dycke A, Selzler KJ, et al 
A phase 3, long-term, open-label safet 
study of Galcanezumab in patients wit 
migraine. BMC Neurology. 2018;18(1): 
1-10. DOI: 10.1186/s12883-018-1193-2
[91] Dodick DW, Silberstein SD,  
Bigal ME, Yeung PP, Goadsby PJ,  
Blankenbiller T, et al. Effect of 
Fremanezumab compared with placebo 
for prevention of episodic migraine. 
Journal of the American Medical 
Association. 2018;319(19):1999. DOI: 
10.1001/jama.2018.4853
[92] Tepper S, Ashina M, Reuter U, 
Brandes JL, Doležil D, Silberstein S, 
et al. Safety and efficacy of erenumab 
for preventive treatment of chronic 
migraine: A randomised, double-blind, 
placebo-controlled phase 2 trial. The 
Lancet Neurology. 2017;16(6):425-434. 
DOI: 10.1016/s1474-4422(17)30083-2
[93] Gandolfi M, Marchioretto F, 
Turrina A, Dimitrova E, Geroin C, 
Valè N. Does myofascial and trigger 
point treatment reduce pain and 
analgesic intake in patients undergoing 
OnabotulinumtoxinA injection due 
to chronic intractable migraine? 
A pilot, single-blind randomized 
controlled trial. European Journal of 
Physical and Rehabilitation Medicine. 
2017;54(1):1-12
[94] Guilbot A, Bangratz M, Ait 
Abdellah S, Lucas C. A combination 
of coenzyme Q10, feverfew and 
magnesium for migraine prophylaxis: 
A prospective observational study. 
BMC Complementary and Alternative 
Medicine. 2017;17(1):1-6. DOI: 10.1186/
s12906-017-1933-7
[95] Silberstein SD, Calhoun AH, 
Lipton RB, Grosberg BM, Cady RK, 
Dorlas S, et al. Chronic migraine 
headache prevention with noninvasive 
vagus nerve stimulation. Neurology. 
2016;87(5):529-538. DOI: 10.1212/
wnl.0000000000002918
